hotspot -WSS

hotspot

author：focus 2025-09-03 14:34:55 - browse：314

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

WSS

EU moves toward latest gene techniques in food production to counter climate change, shortages

5 shark bites reported on Long Island as officials deploy surveillance drones

Military medical care influenced by rank and race, new study finds

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

focus

hotspot

Sign up for D.C. Diagnosis

hotspot

Apple is now the first public company to be valued at $3 trillion

Second House panel advances two

How one medical school became remarkably diverse

Second House panel advances two

ChatGPT in medicine: STAT answers readers' burning questions

When prostate cancer spreads, where it goes matters

At least 13 dead in Texas as scorching temps continue

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

leisure time

China dismisses criticism of top diplomat's comments appearing to push for race

With measles on the rise, a personal story of a devastating disease

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

explore

explore

explore

hotspot